Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Report

Global and Region Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：159
  • REPORT CODE：GMM1004907
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugsmarket, defines the market attractiveness level of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs industry, describes the types of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market and the development prospects and opportunities of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market in Chapter 13.

    By Player:

    • Novartis

    • Roche

    • Neurotech Pharmaceuticals

    • Regeneron Pharmaceuticals

    • Allergan

    • Bayer Healthcare

    By Type:

    • Macular Degeneration Drugs

    • Diabetic Retinopathy Drugs

    By End-User:

    • 50-60 Years Old

    • 60-70 Years Old

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.2 United States Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.4 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.5 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.6 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    • 7.7 South Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2017-2022)

    8 Region and Country-wise Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.4 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.6 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast (2022-2028)

    9 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Macular Degeneration Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Diabetic Retinopathy Drugs Consumption and Growth Rate (2017-2022)

    • 9.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global 50-60 Years Old Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global 60-70 Years Old Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Macular Degeneration Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Diabetic Retinopathy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global 50-60 Years Old Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global 60-70 Years Old Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Competitive Analysis

    • 14.1 Novartis

      • 14.1.1 Novartis Company Details

      • 14.1.2 Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • 14.2 Roche

      • 14.2.1 Roche Company Details

      • 14.2.2 Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • 14.3 Neurotech Pharmaceuticals

      • 14.3.1 Neurotech Pharmaceuticals Company Details

      • 14.3.2 Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • 14.4 Regeneron Pharmaceuticals

      • 14.4.1 Regeneron Pharmaceuticals Company Details

      • 14.4.2 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • 14.5 Allergan

      • 14.5.1 Allergan Company Details

      • 14.5.2 Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • 14.6 Bayer Healthcare

      • 14.6.1 Bayer Healthcare Company Details

      • 14.6.2 Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs

    • Figure Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Picture

    • Table Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption by Country (2017-2022)

    • Figure United States Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Macular Degeneration Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Diabetic Retinopathy Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global 50-60 Years Old Consumption and Growth Rate (2017-2022)

    • Figure Global 60-70 Years Old Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Macular Degeneration Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Diabetic Retinopathy Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 50-60 Years Old Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 60-70 Years Old Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • Table Neurotech Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • Table Regeneron Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service

    • Table Bayer Healthcare (Foundation Year, Company Profile and etc.)

    • Table Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US